Deamidation Mechanism

Deamidation represents non-enzymatic conversion of asparagine and glutamine residues to aspartate and glutamate within protein structures through hydrolysis of amide side chains. This post-translational modification alters protein charge, hydrophobicity, and potentially immunogenicity affecting therapeutic antibody and protein drug stability. Nucleophilic attack on the amide carbonyl by neighbouring hydroxyl or amino groups forms cyclic intermediates that subsequently hydrolyse generating iso-aspartate or aspartate products. Temperature, pH, and ionic strength profoundly influence deamidation rates with elevated conditions substantially accelerating degradation.

Stability assessment of protein therapeutics requires quantitative deamidation monitoring throughout shelf life via mass spectrometry and peptide mapping. Formulation strategies including pH buffering, chelating agents, and antioxidants reduce deamidation rates. Asparagine and glutamine placement in amino acid sequences influences deamidation susceptibility requiring consideration during protein engineering. Post-approval monitoring detects unexpected deamidation patterns warranting manufacturing investigation. Emerging technologies including deuterated water exchange mass spectrometry provide detailed mechanistic insights guiding formulation optimisation.